Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
July 10, 2024 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
July 09, 2024 09:15 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals Announces Proposed Public Offering
July 08, 2024 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it...
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
July 08, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in the U.S. are affected by fibromyalgia, predominantly...
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
July 01, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 01, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
June 28, 2024 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
June 27, 2024 08:36 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals Announces Proposed Public Offering
June 26, 2024 16:40 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it...
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 26, 2024 15:13 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company, today announced that it has...
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
June 25, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix’s live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose TNX-801 vaccination demonstrated efficacy in protecting animals from lethal...